• Matinas BioPharma disclosed a warrant inducement that led to the immediate cash exercise of existing warrants for 7,486,605 common shares at USD 0.35.
• Gross proceeds from the exercises were about USD 2.6 million.
• In exchange, it will issue new unregistered warrants to buy up to 7,486,605 common shares at USD 0.35, subject to stockholder approval.
• Separately, it issued warrants to buy up to 1,642,856 common shares alongside a USD 575,000 Series D convertible preferred stock private placement.
• The shares underlying the exercised existing warrants were registered for resale under an effective Form S-3 registration statement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Matinas BioPharma Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130800PRIMZONEFULLFEED9760825) on July 13, 2026, and is solely responsible for the information contained therein.